| Assessment Status | NCPE Assessment Process complete |
| HTA ID | - |
| Drug | Canagliflozin |
| Brand | Invokana® |
| Indication | Treatment of type 2 diabetes as monotherapy or add-on combination therapy to other glucose-lowering medicinal products including insulin |
| Assessment Process | |
| Rapid review commissioned | 25/11/2013 |
| Rapid review completed | 02/12/2013 |
| Rapid review outcome | Full HTA Recommended |
| Full submission received from Applicant | 17/12/2014 |
| NCPE assessment completed | 29/08/2014 |
| NCPE assessment outcome | Reimbursement not recommended under the submitted pricing structure. |
The HSE has approved reimbursement following confidential price negotiations; December 2014.
